Ratings Iqvia Holdings Inc.

Equities

IQV

US46266C1053

Real-time Estimate Cboe BZX Other stock markets 09:37:26 2023-11-29 am EST			5-day change	1st Jan Change
213.83 ^USD	+1.34%		+1.71%	+2.98%

Nov. 22	Not good enough!
Nov. 22	ANALYST RECOMMENDATIONS : Best Buy, Glencore, Lowe's, Nvidia, Clorox...

Strengths

Analysts covering this company mostly recommend stock overweighting or purchase.
Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

Weaknesses

The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
With an expected P/E ratio at 32.37 and 28.77 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
The company's enterprise value to sales, at 3.38 times its current sales, is high.
The company appears highly valued given the size of its balance sheet.
Revenue estimates are regularly revised downwards for the current and coming years.
Over the past four months, analysts' average price target has been revised downwards significantly.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector : Biotechnology & Medical Research

	1st Jan change	Capi. (M$)	ESG Refinitiv
IQVIA HOLDINGS INC.	+2.98%	38 508 M $	B
SEAGEN INC.	+66.65%	40 404 M $	B
MODERNA, INC.	-56.47%	29 809 M $	B-
LONZA GROUP AG	-24.92%	28 695 M $	A
ICON PUBLIC LIMITED COMPANY	+37.75%	22 029 M $	B-
ALNYLAM PHARMACEUTICALS, INC.	-32.10%	20 250 M $	B
CELLTRION, INC.	+2.80%	17 781 M $	C
UNITED THERAPEUTICS CORPORATION	-17.15%	10 827 M $	B+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-10.41%	10 014 M $	C+
BIO-TECHNE CORPORATION	-25.60%	9 752 M $	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes